News

Deal Announcements

FluGen Flags New Venture Capital Funding

Monday, August 24, 2015 5:30:00 AM PDT | VentureDeal
   Madison, Wisconsin  --  Pharmaceutical technology company FluGen has received $9.4 million in new venture capital equity financing, according to an SEC regulatory filing.

FluGen is focused on developing the most effective vaccine against all forms of influenza.

The company is preparing to enter human trials in 2016 for its flagship REDEE FLU influenza vaccine.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. 

FluGen is seeking additional investment, according to its website.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1